GNS, a leader in the application of causal AI and simulation and “digital twins” to drug discovery, today announced two abstracts and two oral poster presentations highlighting insights from the Gemini digital twin models in Alzheimer’s disease and multiple myeloma will be Clinical Trials at Alzheimer’s Disease Conference (CTAD) in San Francisco and the American Society of Hematology (ASH) in New Orleans.